Propella Therapeutics, Pittsboro firm with 5 employees, sold for $175M
As part of the acquisition, Astellas will acquire Propella's lead asset, a potential treatment for metastatic prostate cancer. Astellas, which opened a $100 million plant in North Carolina in 2022, has run afoul of both U.S. and British authorities in recent years.
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Zac Ezzone Source Type: news
More News: Cancer | Cancer & Oncology | Health Management | Mergers and Aquisitions | Pharmaceuticals | Prostate Cancer | UK Health